NSE ScannerComparison · NSE · data 2026-11-01
Accretion Pharmaceuticals Ltd. vs Brooks Laboratories Limited
In plain words
Size: Accretion Pharmaceuticals Ltd. is about 1.2 times the market value of Brooks Laboratories Limited.
Valuation (P/E): Accretion Pharmaceuticals Ltd. 21.9 vs Brooks Laboratories Limited 13.5.
Return on equity: Accretion Pharmaceuticals Ltd. 27.6% vs Brooks Laboratories Limited 22.3%.
Debt to equity: Accretion Pharmaceuticals Ltd. 0.23 vs Brooks Laboratories Limited 0.07.
Differences in the numbers, not a recommendation of either stock.
Side by side
| ACCPL | BROOKS | |
|---|---|---|
| Price | ₹190.05 | ₹60.56 |
| Market cap | ₹211 cr | ₹179 cr |
| P/E | 21.9 | 13.5 |
| P/B | 3.9 | — |
| ROE | 27.6% | 22.3% |
| ROCE | 38.3% | 4.8% |
| Debt / equity | 0.23 | 0.07 |
| Operating margin | 15.3% | 5.0% |
| Dividend yield | 0.00% | 0.00% |
| Sales growth, 3 years (yearly) | 45.0% | 10.9% |
| Profit growth, 3 years (yearly) | 353.1% | — |
| 1-year return | 234.9% | -43.3% |
| Revenue, last 12 months | ₹90 cr | ₹83 cr |
| Net profit, last 12 months | ₹10 cr | ₹13 cr |
| Latest quarter | — | Jun 2026 |
| Quarter net profit | — | ₹-2 cr |
| Quarter profit vs a year earlier | — | -118.7% |
| Promoter holding | — | 52.62% |
| Health check | Strong (9.1/10) | Average (5.2/10) |
Common questions
Which has a higher P/E, Accretion Pharmaceuticals Ltd. or Brooks Laboratories Limited?
Accretion Pharmaceuticals Ltd. trades at the higher P/E (21.9 against 13.5). A higher P/E means the market pays more for each rupee of past earnings; on its own it does not say which is better.
Which earns a higher return on equity?
Accretion Pharmaceuticals Ltd. (27.6% against 22.3%).
Which carries more debt?
Accretion Pharmaceuticals Ltd. has the higher debt-to-equity ratio (0.23 against 0.07).